Another risk to US travelers—malaria

To individualize preventive measures, rely on reported risk data for specific destinations, planned activities, and patient comorbidities.

Although malaria was eradicated as an endemic disease in the United States in the early 1950s, it still returns yearly in approximately 1500 individuals who travel to foreign countries—most of whom neglected to use prophylactic measures or use them properly. In more than 60 documented cases, these infected individuals have been the source of local transmission in their communities. To reduce the individual and public health risks associated with malaria, this article focuses on steps that international travelers can take to limit their risk of the disease.

What travelers need to know

In 2013, more than 61.5 million residents of the United States traveled abroad, approximately 30% of whom visited malaria-endemic regions: Mexico and equatorial nations in Central and South America; Africa; the Middle East; and South, East, and Southeast Asia. Counseling on appropriate preventive measures fits the Medical Home concept of comprehensive, preventive, patient-centered care, and pre-travel consultation—including a review of health data and itineraries, and patient education—can be a team-based effort.

Begin your planning for malaria prophylaxis by assessing your patient’s individual risk. Key variables are a patient’s detailed itinerary, a credible and current source of information on location-specific malaria prevalence, personal risk factors, and risk tolerance. Shared decision-making is vital and enhances adherence to the prescribed regimen.

Endemicity varies regionally. Without chemoprophylaxis, risk of infection ranges from more than 20% in Papua New Guinea to 0.01% in Central America, with wide exposure risk variations likely, even within regions. Travel to areas of high endemicity requires more aggressive malaria prevention strategies than travel to low-endemicity regions.

Risk of exposure is lower with short visits, business-
only travel, urban-only stays in some countries, day trips to endemic areas, and travel during seasons with lower mosquito burden. Likewise, travelers staying in a hotel with sealed windows will face lower nighttime Anopheles mosquito exposure. In these cases, nonpharmacologic measures alone may be appropriate.

Those at particularly high risk for complicated or lethal malarial infection are children, pregnant women, elderly individuals, and immunocompromised patients. In addition to counseling high-risk patients about prophylactic measures, consider advising against travel in certain circumstances. Among those at highest risk for acquiring malaria are immigrants and refugees traveling to their ancestral homelands to visit friends and relatives (VFR). Many VFR travelers fail to take appropriate prophylactic measures when “going home.” A significant number of cases of travel-acquired malaria occurs in VFR children.

Individualizing prevention directives

The mainstays of malaria prevention include nonpharmacologic and behavioral interventions, as well as chemoprophylaxis. Most cases of malaria in travelers returning to the United States result from the improper implementation of prophylactic measures. Discussing individual risk with travelers is an easy way to bolster adherence to malaria prevention measures, and some evidence suggests it is effective (strength of recommendation [SOR]: C). Other limited studies have also shown that malaria education can improve knowledge about malaria transmission and increase the likelihood that preventive measures will be used.

Recommend nonpharmacologic measures even for those using chemoprophylaxis

Nonpharmacologic interventions such as sleeping under permethrin-treated bednets, wearing long sleeves and full-length pants, treating clothes with permethrin, and applying DEET (N,N-diethyl-meta-toluamide) to exposed skin are effective and have the added benefit of preventing non-malarial arthropod-borne diseases (SOR: B). Studies have shown that, compared with sleeping without nets, the use of insecticide treated-nets can reduce child mortality by 17% and the incidence of uncomplicated malarial episodes by 50%. In areas with malaria transmission, 10% to 30% DEET—used alone or in combination with permethrin-treated clothing—can reduce bite load, although the American Academy of Pediatrics recommends against using DEET in children younger than 2 months of age.

Using these measures in combination from dusk to dawn, when Anopheles mosquitoes are active, has been shown to be effective, although randomized, controlled studies are lacking. Remaining indoors during these peak biting periods is also advisable. In certain areas, and with the right itinerary, the traveler may only need to employ nonpharmacologic methods of preventing malarial infection. Recommend them to all patients traveling to malarial regions, even to individuals using pharmacologic prophylaxis.

Factors determining the need for, and selection of, chemoprophylaxis

When used properly, chemoprophylactic drugs are effective in preventing malaria (SOR: A). Atovaquone-proguanil achieves efficacy of 95% to 100%, while doxycycline, primaquine, and mefloquine are slightly less effective. Chloroquine is effective in 6 regions of the tropics and subtropics where Plasmodium falciparum resistance has not developed. Select a drug based on your assessment of an individual’s level of risk according to the personal itinerary, trip duration and accommodations, cost of medication, tolerance for adverse effects, and other factors (eg, comorbidities, concurrent drug usage, pregnancy).

Location matters. The risk of malaria transmission can vary considerably not only between countries, but also regionally within countries and even between a city and its immediate surroundings. Therefore, select a chemoprophylactic agent based on the specific itinerary, planned activities, the potential for unforeseen additional excursions, and local Plasmodium resistance patterns.
For example, chloroquine is effective only in the Caribbean, Central America, and some countries in the Middle East. Mefloquine resistance has been reported in parts of Cambodia, Thailand, Vietnam, Burma, China, and Laos.

On its Travelers’ Health Web site (www.cdc.gov/travel), the Centers for Disease Control and Prevention (CDC) reports for each country 1) the risk of malaria transmission, 2) areas within the country that pose a risk, 3) evidence of *Plasmodium* drug resistance, 4) which *Plasmodium* species are active, and 5) which chemoprophylactic medications are recommended. Additional Web sites, either free or subscription-based, allow users to view this same information on maps, advise on where insect precautions alone are sufficiently protective, and provide information about the traveler’s risk of contracting other diseases (TABLE 1).

### Table 1

<table>
<thead>
<tr>
<th>Resource</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centers for Disease Control and Prevention</td>
<td>Free site Go to Yellow Book » Contents » Chapter 3 » “Travel Vaccines &amp; Malaria Information, by Country” for country-specific information about the risk of malaria transmission</td>
</tr>
<tr>
<td>VHI Healthcare vhi.exodus.ie/index.asp</td>
<td>Free site Destination-specific information about travel alerts and vaccine recommendations <em>Does not report malaria transmission data</em></td>
</tr>
<tr>
<td>Gideon <a href="http://www.gideononline.com">www.gideononline.com</a></td>
<td>Subscription only Online application that helps with diagnosing infectious diseases and keeping up to date with global health literature</td>
</tr>
<tr>
<td>Travax <a href="http://www.travax.com">www.travax.com</a></td>
<td>Subscription only Information about recommended vaccines and country-specific risk of malaria transmission</td>
</tr>
<tr>
<td>Tropimed <a href="http://www.tropimed.com">www.tropimed.com</a></td>
<td>Subscription only Information about recommended vaccines and country-specific risk of malaria transmission</td>
</tr>
</tbody>
</table>

For example, chloroquine is effective only in the Caribbean, Central America, and some countries in the Middle East. Mefloquine resistance has been reported in parts of Cambodia, Thailand, Vietnam, Burma, China, and Laos.

On its Travelers’ Health Web site (www.cdc.gov/travel), the Centers for Disease Control and Prevention (CDC) reports for each country 1) the risk of malaria transmission, 2) areas within the country that pose a risk, 3) evidence of *Plasmodium* drug resistance, 4) which *Plasmodium* species are active, and 5) which chemoprophylactic medications are recommended. Additional Web sites, either free or subscription-based, allow users to view this same information on maps, advise on where insect precautions alone are sufficiently protective, and provide information about the traveler’s risk of contracting other diseases (TABLE 1).

### Comparative adverse effects of antimalarial agents

A Cochrane Review on the tolerability of chemoprophylactic agents concluded that atovaquone-proguanil and doxycycline were better tolerated than mefloquine (SOR: B). Compared with mefloquine, atovaquone-proguanil led to fewer reports of any adverse effects (relative risk [RR]=0.72), gastrointestinal adverse effects (RR=0.54), and neuropsychiatric adverse events (RR=0.49-0.86, depending on the studies). Doxycycline users have reported fewer neuropsychiatric events (RR=0.84) than mefloquine users. These are relatively small differences, and the authors point out that these figures are based on low-quality evidence. Additional research is likely to have an impact on the confidence in the estimate of effect and to ultimately change the estimate.

Mefloquine is contraindicated in travelers with seizures, active or recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other psychiatric disorders. Compared with mefloquine, atovaquone-proguanil and doxycycline
### Table 2
Comparative dosing schedules and costs of anti-malarial drugs

<table>
<thead>
<tr>
<th>Agent</th>
<th>Adult dose</th>
<th>Pediatric dose</th>
<th>Dosing schedule</th>
<th>Safe in lactation, pregnancy, and in children?</th>
<th>Number of pills for 2 weeks of exposure</th>
<th>Cost to treat during 2-week trip*</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atovaquone-proguanil</td>
<td>250 mg atovaquone/100 mg proguanil</td>
<td>62.5 mg atovaquone/25 mg proguanil</td>
<td>Daily dosing: Start 1-2 days before exposure; Stop 7 days after exposure</td>
<td>Lactation, yes; if breastfeeding &gt;5 kg</td>
<td>22</td>
<td>$85</td>
<td>Contraindicated in those with a creatinine clearance &lt;30 mL/min</td>
</tr>
<tr>
<td></td>
<td>5-8 kg: ½ pediatric tablet</td>
<td>&gt;8-10 kg: ¾ pediatric tablet</td>
<td>&gt;10-20 kg: 1 pediatric tablet</td>
<td>&gt;20-30 kg: 2 pediatric tablets</td>
<td>&gt;30-40 kg: 3 pediatric tablets</td>
<td>&gt;40 kg: 1 adult tablet</td>
<td></td>
</tr>
<tr>
<td></td>
<td>250 mg atovaquone/25 mg proguanil</td>
<td>62.5 mg atovaquone/25 mg proguanil</td>
<td>Weekly dosing: Start 1-2 weeks before exposure; Stop 4 weeks after exposure</td>
<td>Yes, for all</td>
<td>7</td>
<td>$40</td>
<td>May exacerbate psoriasis, lower seizure threshold, or prolong QTc intervals</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>500 mg salt (equal to 300 mg base)</td>
<td>8.3 mg/kg salt (equal to 5 mg/kg base), up to the adult dose of 500 mg salt</td>
<td>Daily dosing: Start 1-2 days before exposure; Stop 4 weeks after exposure</td>
<td>Lactation, no; Pregnancy, no</td>
<td>43</td>
<td>$72</td>
<td>Oral typhoid vaccine Ty21a should be delayed for ≥24 hours after taking a dose of doxycycline. Should not take before going to bed to minimize risk of esophagitis. Risk of photosensitivity can be minimized by avoiding prolonged sun exposure and using sunscreen</td>
</tr>
<tr>
<td></td>
<td>≥8 years of age: 2.2 mg/kg up to adult dose of 100 mg</td>
<td>≥8 years of age: 2.2 mg/kg up to adult dose of 100 mg</td>
<td>Daily dosing: Start 1-2 days before exposure; Stop 4 weeks after exposure</td>
<td>Lactation, no; Pregnancy, no</td>
<td>43</td>
<td>$72</td>
<td>Oral typhoid vaccine Ty21a should be delayed for ≥24 hours after taking a dose of doxycycline. Should not take before going to bed to minimize risk of esophagitis. Risk of photosensitivity can be minimized by avoiding prolonged sun exposure and using sunscreen</td>
</tr>
<tr>
<td></td>
<td>≥8 years of age: 2.2 mg/kg up to adult dose of 100 mg</td>
<td>≥8 years of age: 2.2 mg/kg up to adult dose of 100 mg</td>
<td>Daily dosing: Start 1-2 days before exposure; Stop 4 weeks after exposure</td>
<td>Lactation, no; Pregnancy, no</td>
<td>43</td>
<td>$72</td>
<td>Oral typhoid vaccine Ty21a should be delayed for ≥24 hours after taking a dose of doxycycline. Should not take before going to bed to minimize risk of esophagitis. Risk of photosensitivity can be minimized by avoiding prolonged sun exposure and using sunscreen</td>
</tr>
</tbody>
</table>

G6PD, glucose-6-phosphate dehydrogenase; GI, gastrointestinal; P, plasmodium.

*Approximate price, based on www.goodrx.com October 2014 (prices “without coupon”).
### TABLE 2
Comparative dosing schedules and costs of anti-malarial drugs\(^7,25,26\) (cont’d)

<table>
<thead>
<tr>
<th>Agent</th>
<th>Adult dose</th>
<th>Pediatric dose</th>
<th>Dosing schedule</th>
<th>Safe in lactation, pregnancy, and in children?</th>
<th>Number of pills for 2 weeks of exposure</th>
<th>Cost to treat during 2-week trip*</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mefloquine</td>
<td>250 mg salt (228 mg base)</td>
<td>≤9 kg: 5 mg/kg salt (4.6 mg/kg base)</td>
<td>Weekly dosing Start at least 2 weeks before exposure Stop 4 weeks after exposure</td>
<td>Yes, for all</td>
<td>7</td>
<td>$84</td>
<td>Contraindicated in individuals with seizures, active or recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorders. Use caution in those with a history of depression. Not recommended for those with cardiac conduction abnormalities.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;9-19 kg: ¼ tablet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;19-30 kg: ½ tablet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;30-45 kg: ¾ tablet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;45 kg: 1 tablet</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>52.6 mg salt (equal to 30 mg base)</td>
<td>0.8 mg/kg salt (0.5 mg/kg base) up to the adult dose</td>
<td>Daily dosing Start 1-2 days before exposure Stop 7 days after exposure</td>
<td>Lactation, no Pregnancy, no Children, yes</td>
<td>44 (only 15 mg base pills are available)</td>
<td>$95</td>
<td>Used for primary prophylaxis (in countries where (P) vivax is responsible for &gt;90% of the diagnosed cases of malaria), or for causal prophylaxis after prolonged exposure to (P) vivax or (P) ovale, in conjunction with other chemoprophylactic agent for 14 days after departure from the malarious area. Evaluate for G6PD deficiency before starting the medication. GI upset can be minimized by taking the medication with food.</td>
</tr>
<tr>
<td>Primaquine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

G6PD, glucose-6-phosphate dehydrogenase; GI, gastrointestinal; P, plasmodium.

*Approximate price, based on www.goodrx.com October 2014 (prices “without coupon”).

Cause fewer neuropsychiatric adverse effects (such as vivid dreams, dizziness, anxiety, depression, visual disturbance, or seizures).\(^24\)

Caution is advised when prescribing chloroquine for patients with epilepsy because the medication has the potential to lower the seizure threshold.\(^25\)

Use caution when prescribing mefloquine for patients with cardiac conduction disturbances. Electrocardiogram alterations such as sinus bradycardia, first-degree AV block, prolongation of QTc intervals, and abnormal T wave changes have been reported.\(^26\)

Chloroquine can also prolong QTc intervals.\(^26\)

CONTINUED
When considering chemoprophylaxis, check on Plasmodium resistance patterns in and around destinations and take into account drug adverse effects for those with comorbidities.

Safety in pregnancy and breastfeeding. Malaria in pregnancy is associated with increased rates of anemia, low birth weight, prematurity, intrauterine growth restriction, and infant mortality. Chloroquine and mefloquine are considered safe during pregnancy and breastfeeding. Doxycycline has been associated with increased risk of harm to the fetus. Atovaquone-proguanil can be used in breastfeeding women if the child is ≥5 kg (≥11 lbs). Chemoprophylaxis taken by the mother while breastfeeding does not protect the infant from infection.

Dosing considerations. Mefloquine and chloroquine are dosed weekly; doxycycline and atovaquone-proguanil are taken daily. Travelers staying in a malaria-endemic region for longer periods (months rather than weeks) often prefer the weekly rather than daily medications; however, this may not be possible due to the adverse-effect profile of mefloquine or to traveling in an area with known chloroquine resistance. Some individuals prefer the routine of taking a medication daily, since remembering to take a single dose on the same day each week can be challenging. Others may not want to carry a large number of pills and therefore prefer weekly dosing. Have patients take medications before the trip, to assess tolerability and to ensure adequate blood concentrations before exposure.

Because mefloquine, doxycycline, and chloroquine target only the blood stages of Plasmodium, patients must continue these medications for 4 weeks following the exposure period to ensure adequate coverage as parasites are released from the liver. Because doxycycline is taken daily and has to be continued for 4 weeks following the exposure period, the total number of pills taken is higher for this regimen. Atovaquone-proguanil is active against hepatic and blood stages and can be discontinued a week following the exposure period.

With children, base dosing on body weight and do not exceed the recommended adult dose. When fractions of tablets are used (such as with mefloquine and atovaquone-proguanil dosing), pharmacists can crush tablets and place divided doses in capsules, to be sprinkled as needed into food such as applesauce or jelly. Mefloquine and chloroquine can be given to children of all ages and weights. Although atovaquone-proguanil is approved only for children ≥11 kg (≥24 lbs), dosing schedules have been calculated for children who weigh ≥5 kg. Doxycycline is recommended only for children who are at least 8 years of age.

Cost. For a 2-week exposure period, chloroquine is the least expensive medication (although regions in which it is recommended are limited due to resistance) (TABLE 2).

Ask about accommodations. Since Anopheles mosquitoes feed between dusk and dawn, inquiring about accommodations can further clarify a patient’s malaria risk. Staying in air-conditioned housing (implying that the interior can be sealed) or that has screened windows can reduce exposure to mosquitoes, although data are lacking regarding whether the latter practice reduces the incidence of malaria transmission (SOR: C).

Share decision making. After considering the key factors determining a patient’s level of risk, you may decide to recommend no specific interventions, to advise insect avoidance measures only, to combine insect avoidance with chemoprophylaxis, or to caution against traveling to a malaria-endemic region. The patient’s contribution to the final decision includes personal preferences, values, and risk tolerance—particularly when comorbidities are involved.

When preventive measures fail. Approximately 0.2% of travelers to malaria-endemic regions will become infected, despite proper pre-travel counseling and prophylaxis. In the United States, malaria is often misdiagnosed or improperly treated. The time from initial presentation to correct diagnosis of malaria has been reported as an astonishingly high 4 to 8.5 days, depending on the population. A high index of suspicion is needed and will ensure timely care when any febrile traveler returns from a malaria-endemic area. Be sure to advise patients to seek medical attention if they are febrile upon returning home.
Once suspected, the diagnosis of malaria can be readily confirmed through the use of antibody-, nucleic acid-, or microscopy-based techniques (the latter to directly visualize \textit{Plasmodium} species in blood smears). Although malaria chemoprophylaxis is relatively straightforward, malaria treatment—especially in cases of chemoprophylaxis failures—may not be, and the topic is beyond the scope of this article. For guidance on treating malaria, consult a knowledgeable physician or contact the CDC at www.cdc.gov/malaria/, or at (855) 856-4713 (weekdays, 9 am to 5 pm EST) or (770) 488-7100 (weekends or after normal business hours; ask for the Malaria Branch clinician on call).


correspondence

Mark K. Huntington, MD, PhD, Center for Family Medicine, 1115 East 20th Street, Sioux Falls, SD 57105; mark.huntington@usd.edu


textual references